TG Therapeutics: Biotech Suitors Not Waiting For Clinical Results Seeking Alpha Gilead Science (GILD) acquired Calistoga Pharmaceutics in 2011 before completion of Phase II studies as a single agent in patients with refractory indolent non-hodgkins lymphoma (iNHL), and in combination with rituximab in the treatment of elderly ... |
